Literature DB >> 8652723

Azithromycin in gonorrhoea.

M A Waugh1.   

Abstract

The clinical applications of azithromycin in gonorrhoea, often complicated by simultaneously acquired infection with Chlamydia trachomatis, are reviewed in this paper. Clinical trails from major centres in Europe are compared with a large, more recent US study. At the present time, azithromycin is recommended throughout the world as a useful antibiotic in treatment of gonorrhoea. It has several advantages in that it can be given as single-dose therapy, it can be given where the causative pathogen of urethritis/cervicitis is uncertain, and it is often, therefore, most useful in acute therapy where there is no immediate microbiological back-up. All these considerations are reviewed in detail.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8652723     DOI: 10.1258/0956462961917212

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  3 in total

1.  Rationale for a Neisseria gonorrhoeae Susceptible-only Interpretive Breakpoint for Azithromycin.

Authors:  Ellen N Kersh; Vanessa Allen; Eric Ransom; Matthew Schmerer; Sancta Cyr; Kim Workowski; Hillard Weinstock; Jean Patel; Mary Jane Ferraro
Journal:  Clin Infect Dis       Date:  2020-02-14       Impact factor: 9.079

Review 2.  Azithromycin. A pharmacoeconomic review of its use as a single-dose regimen in the treatment of uncomplicated urogenital Chlamydia trachomatis infections in women.

Authors:  A P Lea; H M Lamb
Journal:  Pharmacoeconomics       Date:  1997-11       Impact factor: 4.981

3.  Pregnancy outcome following gestational exposure to azithromycin.

Authors:  Moumita Sarkar; Cindy Woodland; Gideon Koren; Adrienne R N Einarson
Journal:  BMC Pregnancy Childbirth       Date:  2006-05-30       Impact factor: 3.007

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.